All In Biotech

Drug Trial Radar · NCT00548860

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

Last checked: Nov 20, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,018 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,018

Actual

Start

Oct 2007

Primary completion

Mar 2009

Study completion Jul 2009

Sponsor

Lead sponsor
American Regent, Inc.Industry
Sponsor type
Industry
First posted
Oct 24, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.

Conditions

  • Anemia

Interventions

  • Ferric CarboxymaltoseDrug

  • Standard Medical Care (SMC)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.Time frame: From Day 0 through 30 days after the last dose of study drug.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Luitpold Pharmaceuticals

    Norristown, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.